CN117064769A - 一种多靶点祛眼袋组合物及其制备方法和应用 - Google Patents
一种多靶点祛眼袋组合物及其制备方法和应用 Download PDFInfo
- Publication number
- CN117064769A CN117064769A CN202311241403.0A CN202311241403A CN117064769A CN 117064769 A CN117064769 A CN 117064769A CN 202311241403 A CN202311241403 A CN 202311241403A CN 117064769 A CN117064769 A CN 117064769A
- Authority
- CN
- China
- Prior art keywords
- eye
- target
- stirring
- pouch
- homogenizing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 38
- 238000002360 preparation method Methods 0.000 title claims abstract description 14
- -1 saponin beta-sitosterol phospholipid Chemical class 0.000 claims abstract description 27
- 239000000843 powder Substances 0.000 claims abstract description 24
- 241000157282 Aesculus Species 0.000 claims abstract description 15
- 235000010181 horse chestnut Nutrition 0.000 claims abstract description 15
- 239000001397 quillaja saponaria molina bark Substances 0.000 claims abstract description 15
- 229930182490 saponin Natural products 0.000 claims abstract description 15
- 244000288157 Passiflora edulis Species 0.000 claims abstract description 14
- 235000000370 Passiflora edulis Nutrition 0.000 claims abstract description 14
- 229940076810 beta sitosterol Drugs 0.000 claims abstract description 14
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 claims abstract description 14
- NJKOMDUNNDKEAI-UHFFFAOYSA-N beta-sitosterol Natural products CCC(CCC(C)C1CCC2(C)C3CC=C4CC(O)CCC4C3CCC12C)C(C)C NJKOMDUNNDKEAI-UHFFFAOYSA-N 0.000 claims abstract description 14
- 229950005143 sitosterol Drugs 0.000 claims abstract description 14
- ROTFCACGLKOUGI-JYJNAYRXSA-N (2s)-2-[[(2s)-2-[[(2s)-2-(3-acetamidopropanoylamino)-3-(1h-imidazol-5-yl)propanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1h-imidazol-5-yl)propanoic acid Chemical compound C([C@H](NC(=O)CCNC(=O)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1NC=NC=1)C(O)=O)C1=CN=CN1 ROTFCACGLKOUGI-JYJNAYRXSA-N 0.000 claims abstract description 11
- 241000193830 Bacillus <bacterium> Species 0.000 claims abstract description 10
- 238000000855 fermentation Methods 0.000 claims abstract description 10
- 230000004151 fermentation Effects 0.000 claims abstract description 10
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 10
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 10
- 239000001180 angelica archangelica l. root extract Substances 0.000 claims abstract description 9
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 9
- 239000002994 raw material Substances 0.000 claims abstract description 9
- 239000001100 (2S)-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)chroman-4-one Substances 0.000 claims abstract description 7
- QUQPHWDTPGMPEX-UHFFFAOYSA-N Hesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(COC4C(C(O)C(O)C(C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-UHFFFAOYSA-N 0.000 claims abstract description 7
- QUQPHWDTPGMPEX-UTWYECKDSA-N aurantiamarin Natural products COc1ccc(cc1O)[C@H]1CC(=O)c2c(O)cc(O[C@@H]3O[C@H](CO[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@H]3O)cc2O1 QUQPHWDTPGMPEX-UTWYECKDSA-N 0.000 claims abstract description 7
- APSNPMVGBGZYAJ-GLOOOPAXSA-N clematine Natural products COc1cc(ccc1O)[C@@H]2CC(=O)c3c(O)cc(O[C@@H]4O[C@H](CO[C@H]5O[C@@H](C)[C@H](O)[C@@H](O)[C@H]5O)[C@@H](O)[C@H](O)[C@H]4O)cc3O2 APSNPMVGBGZYAJ-GLOOOPAXSA-N 0.000 claims abstract description 7
- 229940025878 hesperidin Drugs 0.000 claims abstract description 7
- VUYDGVRIQRPHFX-UHFFFAOYSA-N hesperidin Natural products COc1cc(ccc1O)C2CC(=O)c3c(O)cc(OC4OC(COC5OC(O)C(O)C(O)C5O)C(O)C(O)C4O)cc3O2 VUYDGVRIQRPHFX-UHFFFAOYSA-N 0.000 claims abstract description 7
- ARGKVCXINMKCAZ-UHFFFAOYSA-N neohesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(CO)O3)OC3C(C(O)C(O)C(C)O3)O)=CC(O)=C2C(=O)C1 ARGKVCXINMKCAZ-UHFFFAOYSA-N 0.000 claims abstract description 7
- 239000000463 material Substances 0.000 claims description 72
- 238000003756 stirring Methods 0.000 claims description 49
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 29
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 24
- 230000001804 emulsifying effect Effects 0.000 claims description 24
- 239000006071 cream Substances 0.000 claims description 23
- 239000008213 purified water Substances 0.000 claims description 21
- 238000001816 cooling Methods 0.000 claims description 20
- 238000002156 mixing Methods 0.000 claims description 19
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 15
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 12
- 239000002562 thickening agent Substances 0.000 claims description 12
- 229920001577 copolymer Polymers 0.000 claims description 10
- 238000010438 heat treatment Methods 0.000 claims description 10
- 230000003078 antioxidant effect Effects 0.000 claims description 9
- 239000002537 cosmetic Substances 0.000 claims description 9
- 239000003906 humectant Substances 0.000 claims description 9
- CDQSJQSWAWPGKG-UHFFFAOYSA-N butane-1,1-diol Chemical compound CCCC(O)O CDQSJQSWAWPGKG-UHFFFAOYSA-N 0.000 claims description 8
- 229940082500 cetostearyl alcohol Drugs 0.000 claims description 8
- 229960005150 glycerol Drugs 0.000 claims description 8
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 claims description 8
- 229920005862 polyol Polymers 0.000 claims description 8
- 150000003077 polyols Chemical class 0.000 claims description 8
- 239000003755 preservative agent Substances 0.000 claims description 8
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 claims description 8
- 239000003963 antioxidant agent Substances 0.000 claims description 7
- 235000013870 dimethyl polysiloxane Nutrition 0.000 claims description 7
- 239000004205 dimethyl polysiloxane Substances 0.000 claims description 7
- 238000004945 emulsification Methods 0.000 claims description 7
- 239000003995 emulsifying agent Substances 0.000 claims description 7
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 claims description 7
- 230000002335 preservative effect Effects 0.000 claims description 7
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 claims description 6
- OMIGHNLMNHATMP-UHFFFAOYSA-N 2-hydroxyethyl prop-2-enoate Chemical compound OCCOC(=O)C=C OMIGHNLMNHATMP-UHFFFAOYSA-N 0.000 claims description 6
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 claims description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 6
- 235000018936 Vitellaria paradoxa Nutrition 0.000 claims description 6
- 241001135917 Vitellaria paradoxa Species 0.000 claims description 6
- FGUZFFWTBWJBIL-XWVZOOPGSA-N [(1r)-1-[(2s,3r,4s)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] 16-methylheptadecanoate Chemical compound CC(C)CCCCCCCCCCCCCCC(=O)O[C@H](CO)[C@H]1OC[C@H](O)[C@H]1O FGUZFFWTBWJBIL-XWVZOOPGSA-N 0.000 claims description 6
- 229960000458 allantoin Drugs 0.000 claims description 6
- 229940057910 shea butter Drugs 0.000 claims description 6
- 229940057429 sorbitan isostearate Drugs 0.000 claims description 6
- MQWLIFWNJWLDCI-UHFFFAOYSA-L zinc;carbonate;hydrate Chemical compound O.[Zn+2].[O-]C([O-])=O MQWLIFWNJWLDCI-UHFFFAOYSA-L 0.000 claims description 6
- 229940015975 1,2-hexanediol Drugs 0.000 claims description 5
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 claims description 5
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical group CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 claims description 5
- 239000011703 D-panthenol Substances 0.000 claims description 5
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 claims description 5
- 235000004866 D-panthenol Nutrition 0.000 claims description 5
- 239000000043 antiallergic agent Substances 0.000 claims description 5
- 235000015165 citric acid Nutrition 0.000 claims description 5
- PDYOTPOJFZAOIS-UHFFFAOYSA-N decanoic acid;2,2-dimethylpropane-1,3-diol;octanoic acid Chemical compound OCC(C)(C)CO.CCCCCCCC(O)=O.CCCCCCCCCC(O)=O PDYOTPOJFZAOIS-UHFFFAOYSA-N 0.000 claims description 5
- 229960003949 dexpanthenol Drugs 0.000 claims description 5
- 229930182478 glucoside Natural products 0.000 claims description 5
- 150000008131 glucosides Chemical class 0.000 claims description 5
- FHKSXSQHXQEMOK-UHFFFAOYSA-N hexane-1,2-diol Chemical compound CCCCC(O)CO FHKSXSQHXQEMOK-UHFFFAOYSA-N 0.000 claims description 5
- 238000000265 homogenisation Methods 0.000 claims description 5
- 229920006007 hydrogenated polyisobutylene Polymers 0.000 claims description 5
- 229940100460 peg-100 stearate Drugs 0.000 claims description 5
- 229960005323 phenoxyethanol Drugs 0.000 claims description 5
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 4
- TXFPEBPIARQUIG-UHFFFAOYSA-N 4'-hydroxyacetophenone Chemical compound CC(=O)C1=CC=C(O)C=C1 TXFPEBPIARQUIG-UHFFFAOYSA-N 0.000 claims description 4
- 125000003118 aryl group Chemical group 0.000 claims description 4
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 claims description 4
- FOYKKGHVWRFIBD-UHFFFAOYSA-N gamma-tocopherol acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 FOYKKGHVWRFIBD-UHFFFAOYSA-N 0.000 claims description 4
- 239000004519 grease Substances 0.000 claims description 4
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 claims description 4
- 239000003921 oil Substances 0.000 claims description 4
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 claims description 4
- 229940100515 sorbitan Drugs 0.000 claims description 4
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 claims description 4
- 150000005846 sugar alcohols Polymers 0.000 claims description 4
- 229940049964 oleate Drugs 0.000 claims description 3
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims description 3
- DNIAPMSPPWPWGF-VKHMYHEASA-N (+)-propylene glycol Chemical compound C[C@H](O)CO DNIAPMSPPWPWGF-VKHMYHEASA-N 0.000 claims description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 claims description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 claims description 2
- YPFDHNVEDLHUCE-UHFFFAOYSA-N 1,3-propanediol Substances OCCCO YPFDHNVEDLHUCE-UHFFFAOYSA-N 0.000 claims description 2
- 229940035437 1,3-propanediol Drugs 0.000 claims description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 claims description 2
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 claims description 2
- UIVPNOBLHXUKDX-UHFFFAOYSA-N 3,5,5-trimethylhexyl 3,5,5-trimethylhexanoate Chemical compound CC(C)(C)CC(C)CCOC(=O)CC(C)CC(C)(C)C UIVPNOBLHXUKDX-UHFFFAOYSA-N 0.000 claims description 2
- ANZUDYZHSVGBRF-UHFFFAOYSA-N 3-ethylnonane-1,2,3-triol Chemical compound CCCCCCC(O)(CC)C(O)CO ANZUDYZHSVGBRF-UHFFFAOYSA-N 0.000 claims description 2
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 claims description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 claims description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 2
- 229920002125 Sokalan® Polymers 0.000 claims description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims description 2
- BQMNFPBUAQPINY-UHFFFAOYSA-N azane;2-methyl-2-(prop-2-enoylamino)propane-1-sulfonic acid Chemical compound [NH4+].[O-]S(=O)(=O)CC(C)(C)NC(=O)C=C BQMNFPBUAQPINY-UHFFFAOYSA-N 0.000 claims description 2
- 229960001631 carbomer Drugs 0.000 claims description 2
- SOYKEARSMXGVTM-UHFFFAOYSA-N chlorphenamine Chemical compound C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 SOYKEARSMXGVTM-UHFFFAOYSA-N 0.000 claims description 2
- 229960003291 chlorphenamine Drugs 0.000 claims description 2
- 229920006037 cross link polymer Polymers 0.000 claims description 2
- 229940008099 dimethicone Drugs 0.000 claims description 2
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 claims description 2
- 150000002148 esters Chemical class 0.000 claims description 2
- 239000003205 fragrance Substances 0.000 claims description 2
- 229940075529 glyceryl stearate Drugs 0.000 claims description 2
- ACCCMOQWYVYDOT-UHFFFAOYSA-N hexane-1,1-diol Chemical compound CCCCCC(O)O ACCCMOQWYVYDOT-UHFFFAOYSA-N 0.000 claims description 2
- 229940100554 isononyl isononanoate Drugs 0.000 claims description 2
- 239000001630 malic acid Substances 0.000 claims description 2
- 235000011090 malic acid Nutrition 0.000 claims description 2
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 claims description 2
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 claims description 2
- 229960002216 methylparaben Drugs 0.000 claims description 2
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 claims description 2
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 claims description 2
- 239000003973 paint Substances 0.000 claims description 2
- UWJJYHHHVWZFEP-UHFFFAOYSA-N pentane-1,1-diol Chemical compound CCCCC(O)O UWJJYHHHVWZFEP-UHFFFAOYSA-N 0.000 claims description 2
- 229920001495 poly(sodium acrylate) polymer Polymers 0.000 claims description 2
- 229920002401 polyacrylamide Polymers 0.000 claims description 2
- 229920000058 polyacrylate Polymers 0.000 claims description 2
- 229920000166 polytrimethylene carbonate Polymers 0.000 claims description 2
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 claims description 2
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 claims description 2
- 229960004063 propylene glycol Drugs 0.000 claims description 2
- 229960003415 propylparaben Drugs 0.000 claims description 2
- 229910052708 sodium Inorganic materials 0.000 claims description 2
- 239000011734 sodium Substances 0.000 claims description 2
- NNMHYFLPFNGQFZ-UHFFFAOYSA-M sodium polyacrylate Chemical compound [Na+].[O-]C(=O)C=C NNMHYFLPFNGQFZ-UHFFFAOYSA-M 0.000 claims description 2
- 239000000600 sorbitol Substances 0.000 claims description 2
- 229940032094 squalane Drugs 0.000 claims description 2
- 239000011975 tartaric acid Substances 0.000 claims description 2
- 235000002906 tartaric acid Nutrition 0.000 claims description 2
- 229940104261 taurate Drugs 0.000 claims description 2
- LADGBHLMCUINGV-UHFFFAOYSA-N tricaprin Chemical compound CCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCC)COC(=O)CCCCCCCCC LADGBHLMCUINGV-UHFFFAOYSA-N 0.000 claims description 2
- 239000002671 adjuvant Substances 0.000 claims 1
- 230000017531 blood circulation Effects 0.000 abstract description 7
- 230000003110 anti-inflammatory effect Effects 0.000 abstract description 6
- 229940108690 glucosyl hesperidin Drugs 0.000 abstract description 2
- 230000002195 synergetic effect Effects 0.000 abstract description 2
- 230000003501 anti-edematous effect Effects 0.000 abstract 1
- 238000012360 testing method Methods 0.000 description 31
- 230000000694 effects Effects 0.000 description 26
- 230000000052 comparative effect Effects 0.000 description 14
- 206010030113 Oedema Diseases 0.000 description 10
- 235000019197 fats Nutrition 0.000 description 8
- 230000037393 skin firmness Effects 0.000 description 8
- 238000011156 evaluation Methods 0.000 description 7
- 230000036564 melanin content Effects 0.000 description 7
- 230000032683 aging Effects 0.000 description 5
- 239000000686 essence Substances 0.000 description 5
- 210000000744 eyelid Anatomy 0.000 description 5
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 235000006708 antioxidants Nutrition 0.000 description 4
- 229940116229 borneol Drugs 0.000 description 4
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 description 4
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 description 4
- 230000004089 microcirculation Effects 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 150000007949 saponins Chemical class 0.000 description 4
- 230000008961 swelling Effects 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 3
- NENOAJSZZPODGJ-OIMNJJJWSA-N [(2r)-2-[(2r,3r,4s)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] octanoate Chemical compound CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NENOAJSZZPODGJ-OIMNJJJWSA-N 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 150000003254 radicals Chemical class 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 2
- 208000003251 Pruritus Diseases 0.000 description 2
- 208000010340 Sleep Deprivation Diseases 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 230000003266 anti-allergic effect Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000004856 capillary permeability Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 230000002354 daily effect Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 150000003278 haem Chemical class 0.000 description 2
- 230000001969 hypertrophic effect Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000007803 itching Effects 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 229940067606 lecithin Drugs 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 230000001926 lymphatic effect Effects 0.000 description 2
- 210000001365 lymphatic vessel Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 238000005457 optimization Methods 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 2
- 230000000087 stabilizing effect Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000037303 wrinkles Effects 0.000 description 2
- FACFHHMQICTXFZ-UHFFFAOYSA-N 2-(2-phenylimidazo[1,2-a]pyridin-3-yl)ethanamine Chemical compound N1=C2C=CC=CN2C(CCN)=C1C1=CC=CC=C1 FACFHHMQICTXFZ-UHFFFAOYSA-N 0.000 description 1
- PLXMOAALOJOTIY-FPTXNFDTSA-N Aesculin Natural products OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O)[C@H]1Oc2cc3C=CC(=O)Oc3cc2O PLXMOAALOJOTIY-FPTXNFDTSA-N 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 241000125175 Angelica Species 0.000 description 1
- 241000255789 Bombyx mori Species 0.000 description 1
- 206010011469 Crying Diseases 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 235000002673 Dioscorea communis Nutrition 0.000 description 1
- 241000544230 Dioscorea communis Species 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 206010015993 Eyelid oedema Diseases 0.000 description 1
- 235000001287 Guettarda speciosa Nutrition 0.000 description 1
- 206010028311 Muscle hypertrophy Diseases 0.000 description 1
- 240000007817 Olea europaea Species 0.000 description 1
- 208000035753 Periorbital contusion Diseases 0.000 description 1
- 208000012287 Prolapse Diseases 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
- 206010046996 Varicose vein Diseases 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 229940093797 bioflavonoids Drugs 0.000 description 1
- 239000007844 bleaching agent Substances 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 229910021538 borax Inorganic materials 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 201000010251 cutis laxa Diseases 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 238000010612 desalination reaction Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000009499 grossing Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 210000003041 ligament Anatomy 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 230000003692 lymphatic flow Effects 0.000 description 1
- 210000004324 lymphatic system Anatomy 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 230000012042 muscle hypertrophy Effects 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 229940067137 musk ketone Drugs 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 238000012634 optical imaging Methods 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 206010036067 polydipsia Diseases 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 238000007348 radical reaction Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 238000007665 sagging Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- SCPYDCQAZCOKTP-UHFFFAOYSA-N silanol Chemical compound [SiH3]O SCPYDCQAZCOKTP-UHFFFAOYSA-N 0.000 description 1
- 150000004819 silanols Chemical class 0.000 description 1
- 230000008591 skin barrier function Effects 0.000 description 1
- 230000036620 skin dryness Effects 0.000 description 1
- 230000037394 skin elasticity Effects 0.000 description 1
- 239000004328 sodium tetraborate Substances 0.000 description 1
- 235000010339 sodium tetraborate Nutrition 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000036561 sun exposure Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 229940042585 tocopherol acetate Drugs 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 208000027185 varicose disease Diseases 0.000 description 1
- 150000003712 vitamin E derivatives Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
- A61K8/27—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
- A61K8/602—Glycosides, e.g. rutin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/63—Steroids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
- A61K8/645—Proteins of vegetable origin; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/965—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of inanimate origin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/98—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin
- A61K8/987—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin of species other than mammals or birds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/99—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/005—Preparations for sensitive skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/59—Mixtures
- A61K2800/592—Mixtures of compounds complementing their respective functions
- A61K2800/5922—At least two compounds being classified in the same subclass of A61K8/18
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/85—Products or compounds obtained by fermentation, e.g. yoghurt, beer, wine
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Dermatology (AREA)
- Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Inorganic Chemistry (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Cosmetics (AREA)
Abstract
本发明公开了一种多靶点祛眼袋组合物及其制备方法和应用,多靶点祛眼袋组合物包含以下重量份制备原料:0.01~2份马应龙八宝原粉、0.01~2份葡糖基橙皮苷、0.0001~0.05份乙酰基四肽‑5、0.1~5份眼围合剂338Y324、0.01~1份七叶树皂苷β‑谷甾醇磷脂复合物、0.1~10份燕麦紧肤蛋白、0.01~0.5份当归根提取物、0.1~2份鸡蛋果提取物、0.01~0.1份芽孢杆菌发酵产物。本发明特定选用马应龙八宝原粉作为抗炎成分,选用糖基橙皮苷、眼围合剂作为改善血液循环成分,选用七叶树皂苷β‑谷甾醇磷脂复合、乙酰基四肽‑5、鸡蛋果提取物作为抗水肿成分,选用当归根提取物、燕麦紧肤蛋白作为紧致成分,加上芽孢杆菌发酵产物,几大类组分协同作用,大大提高产品的祛眼袋功效。
Description
技术领域
本发明属于护肤品技术领域,具体涉及一种多靶点祛眼袋组合物及其制备方法和应用。
背景技术
眼袋是皮肤韧带松弛造成的眶隔脂肪脱垂引起的眼部老化现象,眼袋不仅会让人显老,还会危害眼部健康。眼袋的类型较多,可以分为:1)脂肪型眼袋:眶隔脂肪堆积膨隆,眶隔结构相对完好,无皮肤松弛和皱纹的情况,多见于18-35岁中青年群体,一般与遗传、睡眠不足、熬夜、用眼过度有关;2)松弛型眼袋:也叫衰老型眼袋,主要是因衰老引起下睑皮肤松弛下垂,下睑皱纹明显,但眶隔脂肪无明显膨出,多见于40-60岁的中老年人群体;3)水肿型眼袋:眼睛周围皮下组织存在多余液体体积,眼部脂肪相对松,容易发生水肿,形成原因一般是由睡眠不足,睡前饮水过量,哭泣等造成的浮肿;4)泪沟型眼袋:既有眼袋又有泪沟,主要是因为脂肪层下垂和肌肉层松弛逐渐形成,多见于30-40岁的中年群体;5)眼轮匝肌肥厚型:主要是因为眼轮匝肌过于肥厚,形成下睑缘下方条状凸起,看起来就像一对超大号的卧蚕,它不属于脂肪造成,而是肌肉肥大造成。
针对已形成的衰老型眼袋、泪沟型眼袋等真性眼袋,最有效的治疗方法就是祛眼袋手术,根据不同的情况,有内切、外切以及眶隔释放等;而对于脂肪型眼袋、水肿型眼袋等假性眼袋可以采用眼霜、眼贴膜等化妆品产品改善和祛除,假性眼袋形成的原因主要有两种:1)水分积累——眼睑水肿,由于淋巴系统循环不畅及毛细血管渗透性增加;2)脂肪积累——眼球衬垫中脂肪前移,且肌肤失去弹性,肌肤组织变弱。
针对上述眼部问题,申请人在早期的专利CN101849898B中公开了一种眼霜及其制备方法,眼霜含有如下成分:珍珠2-16份、硼砂0.2-2份、VE 10-28份、麝香酮0.005-0.05份、冰片0.2-3份、眼围合剂338Y324 30-90份、碳酸锌氢氧化物0.05-2份,该产品具有较强的增加水分能力和持续锁水效果,较好的抑制黑色素能力和增加皮肤亮度能力,具有较好的改善眼部黑眼圈、眼袋和皱纹的效果。
但是,上述眼霜针对祛眼袋的效果不足,为了进一步提高产品的祛眼袋效果,本发明提出了一种多靶点、多维度祛眼袋组合物,针对眼袋形成的原因,多管齐下,从根本上改善眼袋。
发明内容
针对上述技术问题,本发明的目的在于提供一种多靶点祛眼袋组合物及其制备方法和应用,多靶点、多维度祛眼袋,改善眼袋效果好。
为了实现上述目的,本发明采用如下技术方案:
第一方面,本发明提供一种多靶点去眼袋组合物,以重量份计,包括以下制备原料:
上述技术方案中,马应龙八宝原粉由碳酸锌氢氧化物、琥珀粉、珍珠粉按照特定比例混合后制得。研究表明,马应龙八宝原粉具有较好的抗炎作用,可以通过抑制炎症反应、降低血流量的作用对黑眼圈、眼袋均具有较好的改善作用。
葡糖基橙皮苷含高度溶解性及稳定性的生物类黄酮,刺激肌肤的血流量及血液循环,赋予肌肤温暖的肤感,还能有效增加有效成分的吸收和局部新陈代谢,减少眼袋大小,改善皮肤营养,减少炎症,从而防止和改善黑眼圈、眼袋、老化。
乙酰基四肽-5能改善微循环,促进液体排泄,抑制水分从血管渗漏入组织,降低糖化反应,紧致眼周轮廓,唤启肌肤潜能,能有效解决水肿型眼袋,改善黑眼圈。
眼围合剂338Y324结合中西医学理念的配方设计,标本兼治,整体局部兼顾,作用缓急相济成分精选,功能搭配,效果经市场验证,含五种植物精华、三种硅烷醇、两种美白剂,成分丰富,可促进微循环;该成分同时含三种活性硅烷醇,具备紧致,抗衰功效。
七叶树皂苷β-谷甾醇磷脂复合物由七叶树皂苷、β-谷甾醇、卵磷脂采用phytosome技术复合而成,其作为微循环和淋巴流动改善剂,可以减少静息血液流动和肿胀;其中,七叶树皂苷通过促进毛细血管中水分的交换来缓解静脉曲张,消除水肿,七叶树皂苷和β-谷甾醇还具有较好的抗炎性和抗氧化作用,对胶原蛋白和弹性蛋白结构有稳定作用;七叶树皂苷、β-谷甾醇、卵磷脂phytosome技术复配形成脂质体,在皮肤上起到类似蓄水池的作用,有利于活性成分的经皮渗透,从而增强功效和肌肤亲和性,使有效成分的释放时间更持久,从而具有更好的生物利用度,还可以改善产品的安全性和配伍性。
鸡蛋果提取物又称西番莲果提取物,紫外线及年龄增加会导致淋巴机能下降,而鸡蛋果提取物通过帮助淋巴管的新生,提高淋巴管的排毒功效,通过修护淋巴部位,可以减少眼部积聚的液体量,消除眼袋水肿,提高皮肤的新陈代谢。
当归根提取物被广泛用于活血的化妆品中,得益于当归的活血化瘀、改善皮肤微循环的作用,当归根提取物还具有很好的SOD样活性,能够抑制超氧自由基引起的膜脂质过氧化反应和自由基反应,以及与生物膜磷脂结合保护膜脂质等多种机理拮抗自由基对组织的损害,对自由基阻滞所致的面色灰暗或生疮肿,都有特效。
燕麦紧肤蛋白是一种源自于燕麦蛋白复合物,具有即时紧致的效果,可以使皮肤产生瞬时紧绷的感觉,祛眼袋效果显著,其同时还兼具保湿、成膜、延缓衰老及光滑肌肤的作用。
芽孢杆菌发酵产物是一种嗜极微生物的提取物,具有降解血红素的分解产物胆红素的能力,还能进胶原蛋白生成,提高皮肤紧致度,祛眼袋效果佳,还能有效缓解眼纹、黑眼圈。
作为本发明技术方案的优选,所述马应龙八宝原粉为质量比80~100:0.1~2:0.1~2碳酸锌氢氧化物、琥珀粉、珍珠粉混合得到的混合物;更优选地,碳酸锌氢氧化物、琥珀粉、珍珠粉的质量比为90~100:0.1~1:0.5~2。
作为本发明技术方案的优选,上述组合物中还可以添加抗氧化剂、保湿剂、抗敏剂中的一种或多种。更具体地来说,所述抗氧化剂优选为生育酚乙酸酯,其属于维生素E衍生物,其稳定性较好,在化妆品中经常作为抗氧化剂使用,具有很好的抗氧化效果,在保湿和维持结缔组织,以及保护皮肤不受紫外线伤害都有很好表现。
其中,所述保湿剂优选自乳木果油、尿囊素中的一种或多种,其中,乳木果油是一种天然的保湿剂,能够为皮肤提供水分和养分,防止皮肤干燥;尿囊素具有抗炎、抗过敏作用,对于皮肤炎症、过敏反应有一定的缓解作用。能够增加皮肤角质层的吸水能力,同时增加角质层的水分含量,从而起到良好的保湿作用。
其中,所述抗敏剂优选为舒敏佳,其是一种具备抗敏功效的化妆品植物组方功效原料。从抑制组胺引发的瘙痒,安抚止痒,抑制炎症因子/介质释放,抗炎舒缓,降低毛细血管通透性,祛红消肿,长期使用,能修复肌肤屏障,并从五个维度降低肌肤敏感症状,即刻缓解肌肤敏感的不适反应。
作为本发明技术方案的优选,以重量份计,所述多靶点去眼袋组合物包括以下制备原料:
第二方面,本发明提供一种上述多靶点去眼袋组合物的制备方法,包括如下步骤:将配方量的各组分加入纯化水中进行混合,即得。
第三方面,本发明提供上述多靶点去眼袋组合物在制备化妆品中的应用。
第四方面,本发明提供一种多靶点祛眼袋眼霜,由权利要求1~4上述多靶点去眼袋组合物和辅料制备得到。也即为了改良感官性、赋予皮肤营养、防止品质劣化等,可以在不损害本发明效果的范围内,在本发明所述多靶点祛眼袋组合物中可根据需要适当添加除上述成分以外一般用于眼部化妆品中的各种成分。
作为本发明技术方案的进一步优选,所述辅料选自乳化剂、多元醇、油脂、增稠剂、pH调节剂、防腐剂、芳香剂、纯化水中的一种或多种。
作为本发明技术方案的更进一步优选,所述乳化剂选自鲸蜡硬脂基葡糖苷、鲸蜡硬酯醇、甘油硬脂酸酯、PEG-100硬脂酸酯、鲸蜡硬脂醇橄榄油酸酯、山梨坦橄榄油酸酯中的一种或多种;所述多元醇选自甘油、D-泛醇、丙二醇、丁二醇、山梨醇、双丙甘醇、1,3-丙二醇、戊二醇、己二醇中的一种或多种;所述油脂选自聚二甲基硅氧烷、聚二甲基硅氧烷醇、环五聚二甲基硅氧烷、聚二甲基硅氧烷交联聚合物、氢化聚异丁烯、肉豆蔻酸异丙酯、辛酸/癸酸甘油三酯、异壬酸异壬酯、新戊二醇二辛酸酯/二癸酸酯、角鲨烷中的一种或多种;所述增稠剂选自聚丙烯酸酯交联聚合物-6、丙烯酸羟乙酯/丙烯酰二甲基牛磺酸钠共聚物、山梨坦异硬脂酸酯、聚丙烯酰基二甲基牛磺酸钠、丙烯酰二甲基牛磺酸铵/VP共聚物、聚丙烯酸钠、聚丙烯酰胺、丙烯酸(酯)类/C10-30烷醇丙烯酸酯类交联共聚物、卡波姆中的一种或多种;所述pH调节剂选自酒石酸、柠檬酸、苹果酸中的一种或多种;所述芳香剂选自冰片、香精中的一种或两种;所述防腐剂选自苯氧乙醇、乙基己基甘油、氯苯甘醚、羟苯甲酯、对羟基苯乙酮、羟苯丙酯、1,2-己二醇、山梨坦辛酸酯一种或多种。
更进一步优选地,所述增稠剂包括丙烯酸羟乙酯/丙烯酰二甲基牛磺酸钠共聚物、山梨坦异硬脂酸酯。本增稠剂使用时无需提前溶解分散,只需在搅拌下加入水相或水与油的混合物,即可瞬间形成优质膏体,操作简单方便。具备优异的乳化稳定能力,可稳定乳化几乎所有的化妆品油类,并获得理想的膏体稠度。只需少量添加,即可明显改善传统配方产品的外观及稳定性,并减少乳化剂的用量。可满足优质乳霜对稠度的要求,并具优异的增稠赋形效果。作为一款源自生态设计开发的聚合物增稠剂,不含EO(环氧乙烷),对环境友好。与传统常规增稠剂比,具有良好的耐电解质性,能够在不同的水质条件下保持稳定的性能。同时赋予轻盈、缎面般的肤感,能够赋予产品轻盈、丝滑的肤感,为用户提供舒适的护肤体验。
第五方面,本发明还提供一种上述多靶点祛眼袋眼霜的制备方法,包括如下步骤:
(1)将第一保湿剂、燕麦紧肤蛋白、纯化水加入到乳化罐中,加热,均质3~5min,搅拌混合均匀,得物料1;
(2)将油脂、乳化剂、第二保湿剂、抗氧化剂、第一防腐剂加入到预处理罐中,加热,均质搅拌混合均匀;
(3)预处理罐保持80~85℃,随后再加入马应龙八宝原粉、第一多元醇,均质搅拌混合均匀,得物料2;
(4)乳化罐保持80~85℃,将步骤(3)所得物料2加入到步骤(1)的物料1中,真空均质5~8min,搅拌5~8min,随后继续搅拌3~5min至料体均匀,得物料3;
(5)向步骤(4)所得物料3中加入第二多元醇、增稠剂,真空均质5~10min,随后继续搅拌3~5min,得物料4;
(6)将乳化罐降温至60~65℃,随后向步骤(5)所得物料4中加入眼围合剂338Y324、抗敏剂、乙酰基四肽-5、糖基橙皮苷、第三多元醇、当归根提取物、鸡蛋果提取物、芽孢杆菌发酵产物,真空均质1~2min,搅拌均匀,得物料5;
(7)将乳化罐降温至50~55℃,随后向步骤(6)所得物料5中加入纯化水、七叶树皂苷β谷甾醇磷脂复合物,真空均质1~2min,搅拌均匀,得物料6;
(8)将乳化罐降温至40~45℃,随后向步骤(7)所得物料6中加入纯化水、pH调节剂、第四多元醇、芳香剂、第二防腐剂,真空均质1~2min,搅拌均匀;
(9)将乳化罐降温至35~40℃,真空均质1~3min,随后继续搅拌15~25min,即得所述多靶点祛眼袋眼霜。
与现有技术相比,本发明具有以下有益效果:
(1)本发明提供的多靶点祛眼袋组合物,从抗炎、改善血液循环、抗水肿以及紧致多靶点入手,特定选用马应龙八宝原粉作为抗炎成分,选用糖基橙皮苷、眼围合剂作为改善血液循环成分,选用七叶树皂苷β-谷甾醇磷脂复合、乙酰基四肽-5、鸡蛋果提取物作为抗水肿成分,选用当归根提取物、燕麦紧肤蛋白作为紧致成分,加上芽孢杆菌发酵产物,几大类组分协同作用,大大提高产品的祛眼袋功效。
(2)本发明选用的七叶树皂苷β谷甾醇磷脂复合物大大提高了产品的生物利用度,放大成分功效,改善眼周循环,同时复配乙酰基四肽-5、鸡蛋果提取物,最大化的防止体液堆积,紧致眼周轮廓,唤启肌肤潜能,精准淡化眼袋。
总之,本发明选用的活性成分和辅料相配合,实现了极佳的祛眼袋之功效,制备方法简单。
附图说明
图1为实施例3组中的受试者眼周肌肤祛眼袋效果图(VISIA-CR Standard 2光源模式照片);
图2为实施例3组中的受试者眼周肌肤祛眼袋效果图(Derma-TOP-V3照片)。
具体实施方式
下面将结合本发明实施方式,对本发明实施方式中的技术方案进行清楚、完整地描述,显然,所描述的实施方式仅仅是本发明一部分实施方式,而不是全部的实施方式。基于本发明中的实施方式,本领域普通技术人员在没有做出创造性劳动前提下所获得的所有其他实施方式,都属于本发明保护的范围。
需要特别说明的是,本发明实施例中部分物质信息如下:
本发明实施例中所用七叶树皂苷β-谷甾醇磷脂复合物购自广州市奥雪化工有限公司;
本发明实施例中所用鸡蛋果提取物购自广州同一化学有限公司;
本发明实施例中所用燕麦紧肤蛋白购自北京东方淼森生物科技有限公司;
本发明实施例中所用乙酰基四肽-5购自上海兆衡实业有限公司;
本发明实施例中所用眼围合剂338Y324购自上海百好博生物科技有限公司;
本发明实施例中所使用马应龙八宝原粉由碳酸锌氢氧化物、琥珀粉、珍珠粉按质量比为100:0.5:1混合得到;
本发明实施例中所用芽孢杆菌发酵产物的商品名为Meiview,购自广州同一化学有限公司。
实施例1
一种多靶点祛眼袋组合物,以重量(g)计,包括以下成分:
本实施例中,还提供一种上述组合物的制备方法,包括:将配方量的组分加入适量纯化水中进行混合,即得所述组合物。
实施例2
一种多靶点祛眼袋组合物,以重量(g)计,包括以下成分:
本实施例中,还提供一种上述组合物的制备方法,包括:将配方量的组分加入适量纯化水中进行混合,即得所述组合物。
实施例3
一种多靶点祛眼袋眼霜,以重量(g)计,由以下原料制成:
本实施例中,还提供一种上述多靶点祛眼袋眼霜的制备方法,包括如下步骤:
(1)将A相中的尿囊素、燕麦紧肤蛋白、纯化水加入到乳化罐中,加热,均质4min,搅拌混合均匀,得物料1;
(2)将B相中的氢化聚异丁烯、聚二甲基硅氧烷、新戊二醇二辛酸酯/二癸酸酯以及鲸蜡硬脂醇/鲸蜡硬脂基葡糖苷、鲸蜡硬脂醇、鲸蜡硬脂醇/PEG-100硬脂酸酯、生育酚乙酸酯、乳木果油、山梨坦辛酸酯加入到预处理罐中,加热,均质搅拌混合均匀;
(3)预处理罐保持85℃,随后加入C相中的马应龙八宝原粉、甘油,均质搅拌混合均匀,得物料2;
(4)乳化罐保持80℃,将步骤(3)所得物料2加入到步骤(1)的物料1中,真空均质6min,搅拌6min,随后继续搅拌4min至料体均匀,得物料3;
(5)向步骤(4)所得物料3中加入D相中的丁二醇、丙烯酸羟乙酯/丙烯酰二甲基牛磺酸钠共聚物/山梨坦异硬脂酸酯,真空均质8min,随后继续搅拌4min,得物料4;
(6)将乳化罐降温至62℃,随后向步骤(5)所得物料4中加入E相中的眼围合剂338Y324、舒敏佳、乙酰基四肽-5、糖基橙皮苷、D-泛醇、当归根提取物、鸡蛋果提取物、芽孢杆菌发酵产物,真空均质1~2min,搅拌均匀,得物料5;
(7)将乳化罐降温至52℃,随后向步骤(6)所得物料5中加入F相中的纯化水、七叶树皂苷β谷甾醇磷脂复合物,真空均质2min,搅拌均匀,得物料6;
(8)将乳化罐降温至45℃,随后向步骤(7)所得物料6中加入G相中的纯化水、柠檬酸以及H相中的丁二醇、冰片、1,2-己二醇、苯氧乙醇/乙基己基甘油、香精,真空均质1~2min,搅拌均匀;
(9)将乳化罐降温至37℃,真空均质2min,随后继续搅拌20min,即得所述多靶点祛眼袋眼霜。
实施例4
一种多靶点祛眼袋眼霜,以重量(g)计,由以下原料制成:
本实施例中,还提供一种上述多靶点祛眼袋眼霜的制备方法,包括如下步骤:
(1)将A相中的尿囊素、燕麦紧肤蛋白、纯化水加入到乳化罐中,加热,均质4min,搅拌混合均匀,得物料1;
(2)将B相中的氢化聚异丁烯、聚二甲基硅氧烷、新戊二醇二辛酸酯/二癸酸酯以及鲸蜡硬脂醇/鲸蜡硬脂基葡糖苷、鲸蜡硬脂醇、鲸蜡硬脂醇/PEG-100硬脂酸酯、生育酚乙酸酯、乳木果油、山梨坦辛酸酯加入到预处理罐中,加热,均质搅拌混合均匀;
(3)预处理罐保持85℃,随后加入C相中的马应龙八宝原粉、甘油,均质搅拌混合均匀,得物料2;
(4)乳化罐保持80℃,将步骤(3)所得物料2加入到步骤(1)的物料1中,真空均质6min,搅拌6min,随后继续搅拌4min至料体均匀,得物料3;
(5)向步骤(4)所得物料3中加入D相中的丁二醇、丙烯酸羟乙酯/丙烯酰二甲基牛磺酸钠共聚物/山梨坦异硬脂酸酯,真空均质8min,随后继续搅拌4min,得物料4;
(6)将乳化罐降温至62℃,随后向步骤(5)所得物料4中加入E相中的眼围合剂338Y324、舒敏佳、乙酰基四肽-5、糖基橙皮苷、D-泛醇、当归根提取物、鸡蛋果提取物、芽孢杆菌发酵产物,真空均质1~2min,搅拌均匀,得物料5;
(7)将乳化罐降温至52℃,随后向步骤(6)所得物料5中加入F相中的纯化水、七叶树皂苷β谷甾醇磷脂复合物,真空均质2min,搅拌均匀,得物料6;
(8)将乳化罐降温至45℃,随后向步骤(7)所得物料6中加入G相中的纯化水、柠檬酸以及H相中的丁二醇、冰片、1,2-己二醇、苯氧乙醇/乙基己基甘油、香精,真空均质1~2min,搅拌均匀;
(9)将乳化罐降温至37℃,真空均质2min,随后继续搅拌20min,即得所述多靶点祛眼袋眼霜。
实施例5
一种多靶点祛眼袋眼霜,以重量(g)计,由以下原料制成:
本实施例中,还提供一种上述多靶点祛眼袋眼霜的制备方法,包括如下步骤:
(1)将A相中的尿囊素、燕麦紧肤蛋白、纯化水加入到乳化罐中,加热,均质4min,搅拌混合均匀,得物料1;
(2)将B相中的氢化聚异丁烯、聚二甲基硅氧烷、新戊二醇二辛酸酯/二癸酸酯以及鲸蜡硬脂醇/鲸蜡硬脂基葡糖苷、鲸蜡硬脂醇、鲸蜡硬脂醇/PEG-100硬脂酸酯、生育酚乙酸酯、乳木果油、山梨坦辛酸酯加入到预处理罐中,加热,均质搅拌混合均匀;
(3)预处理罐保持85℃,随后加入C相中的马应龙八宝原粉、甘油,均质搅拌混合均匀,得物料2;
(4)乳化罐保持80℃,将步骤(3)所得物料2加入到步骤(1)的物料1中,真空均质6min,搅拌6min,随后继续搅拌4min至料体均匀,得物料3;
(5)向步骤(4)所得物料3中加入D相中的丁二醇、丙烯酸羟乙酯/丙烯酰二甲基牛磺酸钠共聚物/山梨坦异硬脂酸酯,真空均质8min,随后继续搅拌4min,得物料4;
(6)将乳化罐降温至62℃,随后向步骤(5)所得物料4中加入E相中的眼围合剂338Y324、舒敏佳、乙酰基四肽-5、糖基橙皮苷、D-泛醇、当归根提取物、鸡蛋果提取物、芽孢杆菌发酵产物,真空均质1~2min,搅拌均匀,得物料5;
(7)将乳化罐降温至52℃,随后向步骤(6)所得物料5中加入F相中的纯化水、七叶树皂苷β谷甾醇磷脂复合物,真空均质2min,搅拌均匀,得物料6;
(8)将乳化罐降温至45℃,随后向步骤(7)所得物料6中加入G相中的纯化水、柠檬酸以及H相中的丁二醇、冰片、1,2-己二醇、苯氧乙醇/乙基己基甘油、香精,真空均质1~2min,搅拌均匀;
(9)将乳化罐降温至37℃,真空均质2min,随后继续搅拌20min,即得所述多靶点祛眼袋眼霜。
对比例1
与实施例3比,区别仅在于E组分中不加鸡蛋果提取物,其他组分及制备方法均一致。
对比例2
与实施例3相比,区别仅在于F组分中不加七叶树皂苷β-谷甾醇磷脂复合物替换为七叶树皂苷,其他组分及制备方法均一致。
试验例:人体功效评价试验
本发明以实施例3和对比例1~2制得的眼霜作为测试产品进行人体功效评价试验。
1、评估指标
(1)皮肤紧致度F4值
测量仪器:皮肤弹性测试仪Cutometer MPA580(Courage&Khazaka,德国)。测量要求:测试3次取平均值。
参数解释:F4值越低,说明皮肤紧致度越好。单位:无量纲。
(2)皮肤黑色素含量MI值
测量仪器:皮肤黑色素和血红素测试仪Mexameter MX 18(Courage&Khazaka,德国)。
测量要求:测试3次取平均值。
参数解释:MI值表征皮肤黑色素含量,数值越高,说明皮肤中黑色素含量越高。单位:无量纲。
(3)眼袋体积
测量仪器:皮肤快速光学成像系统Derma TOP-V3(EO-TECH,法国)。
测量要求:采集图像1次(正面),图像分析1次。
参数解释:值越高,说明眼袋体积越大。值越低,说明眼袋体积越小。单位:mm3。
(4)主观评估指标
表1主观评估方法
2、试验方法
选取30例左、右两侧(眼角)F4均值>6,眼袋3~4级,有色素型黑眼圈,年龄范围在30~60岁的中国健康受试者,分为3组,每组10人,分别连续使用测试产品28天。在使用测试产品14天和28天时进行测试,每位受试者测试3次取平均值,再利用SPSS软件进行统计分析。
受试者每天早晚洁面后,取适量产品涂于眼周至吸收,替换日常使用的部产品。整个测试期间不能进行长时间日晒、户外运动、旅游等,整个测试期间不得使用与产品功效相似的化妆品或药品,测试期间受试者不得改变日常护理习惯。
测试环境为温度20.2℃~22.0℃,湿度42.3%~54.2%RH。
3、试验结果
(1)皮肤紧致度F4值
皮肤紧致度F4值试验结果见下表2。由表可知,使用实施例产品14天后,眼周皮肤紧致度F4值就表现出显著降低,使用产品28天后,皮肤紧致度F4值进一步降低,该产品眼部紧致效果较好;使用对比例产品14天后,皮肤紧致度改善不明显,由此可知,本发明实施例产品对眼部肌肤的紧致效果远优于对比例产品。
表2受试者使用产品前后皮肤紧致度F4值测试结果(X±S,n=10)
(与使用产品前比较,*P<0.05,**P<0.01)
(2)皮肤黑色素含量MI值
皮肤黑色素含量MI值试验结果见表3。由表可知,使用实施例产品14天和使用产品28天后,皮肤黑色素含量MI值均显著升高,该产品祛眼袋效果较好且起效快,对比可知,实施例产品对眼部肌肤的祛眼袋效果优于对比例产品。
表3受试者使用产品前后皮肤黑色素含量MI值结果(X±S,n=10)
(与使用产品前比较,*P<0.05,**P<0.01)
(3)眼袋体积结果
眼袋体积试验结果见表4。由表可知,使用测试产品2周,下眼睑眼袋体积显著性降低15.30%(p<0.01),使用测试产品4周,下眼睑眼袋体积显著性降低15.87%(p<0.001),表明产品具有优秀的祛眼袋功效,本发明实施例产品对眼部脆弱皮肤的祛眼袋效果优于对比例产品。
表4受试者使用产品前后的眼袋体积测试结果(X±S,n=10)
(与使用产品前比较,*P<0.05,**P<0.01)
(4)专家评估结果
在30例眼袋3~4级的受试者中,产品测试前,实施例3产品试验组中有6名受试者为4级眼袋,测试产品试用28天后,6名受试者均从4级眼袋缓解至3级眼袋。
产品测试前,对比例1产品试验组中的5名受试者为4级眼袋,测试产品试用28天后,有3名受试者从4级眼袋缓解至3级眼袋。
产品测试前,对比例2产品试验组中有6名受试者为4级眼袋,测试产品试用28天后,有4名受试者从4级眼袋缓解至3级眼袋。
(5)自我评估结果
测试产品试用28天后,要求受试者填写问卷,设置选项包括非常同意、比较同意、既不同意也不反对、比较不同意和非常不同意,并计算非常同意和比较同意受试者占比。自我评估结果见表5。
表5使用产品28天后眼周肌肤状态自评反馈情况
试验例 | 实施例3 | 对比例1 | 对比例2 |
眼袋明显淡化 | 100% | 90% | 80% |
眼袋体积明显减少 | 100% | 70% | 80% |
眼周水肿明显减轻 | 100% | 90% | 90% |
眼周紧致饱满度提升 | 100% | 90% | 100% |
产品整体满意度 | 100% | 80% | 80% |
由表5可知,受试者使用产品28天后,100%的受试者对实施例产品祛眼袋效果满意(包括非常满意和比较满意),80%的受试者对对比例1、对比例2中产品祛眼袋效果满意(包括非常满意和比较满意),所以受试者使用过程中眼部肌肤未出现不适感。
申请人声明,本发明通过上述实施例来说明本发明的技术方案,但本发明并不局限于上述实施例,即不意味着本发明必须依赖上述实施例才能实施。所属技术领域的技术人员应该明了,对本发明的任何改进,对本发明产品个别原料的等效替换及辅助成分的添加、具体方式的选择等,均落在本发明的保护范围和公开范围之内。
Claims (10)
1.一种多靶点去眼袋组合物,其特征在于,以重量份计,包括以下制备原料:
2.根据权利要求1所述的一种多靶点去眼袋组合物,其特征在于,所述马应龙八宝原粉由碳酸锌氢氧化物、琥珀粉、珍珠粉按照质量比80~100:0.1~2:0.1~2混合得到。
3.根据权利要求1所述的一种多靶点去眼袋组合物,其特征在于,还包括抗氧化剂、保湿剂、抗敏剂中的一种或多种。
4.根据权利要求3所述的一种多靶点去眼袋组合物,其特征在于,所述抗氧化剂为生育酚乙酸酯;所述保湿剂选自乳木果油、尿囊素中的一种或多种;所述抗敏剂为舒敏佳。
5.一种权利要求1~4任一项所述多靶点去眼袋组合物的制备方法,其特征在于,包括如下步骤:将配方量的各组分加入纯化水中进行混合,即得。
6.一种权利要求1~4任一项所述多靶点去眼袋组合物在制备化妆品中的应用。
7.一种多靶点祛眼袋眼霜,其特征在于,由权利要求1~4任一项所述多靶点去眼袋组合物和辅料制备得到。
8.根据权利要求7所述的一种多靶点祛眼袋眼霜,其特征在于,所述辅料选自乳化剂、多元醇、油脂、增稠剂、pH调节剂、防腐剂、芳香剂、纯化水中的一种或多种。
9.根据权利要求8所述的一种多靶点祛眼袋眼霜,其特征在于,所述乳化剂选自鲸蜡硬脂基葡糖苷、鲸蜡硬酯醇、甘油硬脂酸酯、PEG-100硬脂酸酯、鲸蜡硬脂醇橄榄油酸酯、山梨坦橄榄油酸酯中的一种或多种;
所述多元醇选自甘油、D-泛醇、丙二醇、丁二醇、山梨醇、双丙甘醇、1,3-丙二醇、戊二醇、己二醇中的一种或多种;
所述油脂选自聚二甲基硅氧烷、聚二甲基硅氧烷醇、环五聚二甲基硅氧烷、聚二甲基硅氧烷交联聚合物、氢化聚异丁烯、肉豆蔻酸异丙酯、辛酸/癸酸甘油三酯、异壬酸异壬酯、新戊二醇二辛酸酯/二癸酸酯、角鲨烷中的一种或多种;
所述增稠剂选自聚丙烯酸酯交联聚合物-6、丙烯酸羟乙酯/丙烯酰二甲基牛磺酸钠共聚物、山梨坦异硬脂酸酯、聚丙烯酰基二甲基牛磺酸钠、丙烯酰二甲基牛磺酸铵/VP共聚物、聚丙烯酸钠、聚丙烯酰胺、丙烯酸(酯)类/C10-30烷醇丙烯酸酯类交联共聚物、卡波姆中的一种或多种;
所述pH调节剂选自酒石酸、柠檬酸、苹果酸中的一种或多种;
所述芳香剂选自冰片、香精中的一种或两种;
所述防腐剂选自苯氧乙醇、乙基己基甘油、氯苯甘醚、羟苯甲酯、对羟基苯乙酮、羟苯丙酯、1,2-己二醇、山梨坦辛酸酯一种或多种。
10.一种权利要求7~9任一项所述多靶点祛眼袋眼霜的制备方法,其特征在于,包括如下步骤:
(1)将第一保湿剂、燕麦紧肤蛋白、纯化水加入到乳化罐中,加热,均质3~5min,搅拌混合均匀,得物料1;
(2)将油脂、乳化剂、第二保湿剂、抗氧化剂、第一防腐剂加入到预处理罐中,加热,均质搅拌混合均匀;
(3)预处理罐保持80~85℃,随后再加入马应龙八宝原粉、第一多元醇,均质搅拌混合均匀,得物料2;
(4)乳化罐保持80~85℃,将步骤(3)所得物料2加入到步骤(1)的物料1中,真空均质5~8min,搅拌5~8min,随后继续搅拌3~5min至料体均匀,得物料3;
(5)向步骤(4)所得物料3中加入第二多元醇、增稠剂,真空均质5~10min,随后继续搅拌3~5min,得物料4;
(6)将乳化罐降温至60~65℃,随后向步骤(5)所得物料4中加入眼围合剂338Y324、抗敏剂、乙酰基四肽-5、糖基橙皮苷、第三多元醇、当归根提取物、鸡蛋果提取物、芽孢杆菌发酵产物,真空均质1~2min,搅拌均匀,得物料5;
(7)将乳化罐降温至50~55℃,随后向步骤(6)所得物料5中加入纯化水、七叶树皂苷β谷甾醇磷脂复合物,真空均质1~2min,搅拌均匀,得物料6;
(8)将乳化罐降温至40~45℃,随后向步骤(7)所得物料6中加入纯化水、pH调节剂、第四多元醇、芳香剂、第二防腐剂,真空均质1~2min,搅拌均匀;
(9)将乳化罐降温至35~40℃,真空均质1~3min,随后继续搅拌15~25min,即得所述多靶点祛眼袋眼霜。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202311241403.0A CN117064769A (zh) | 2023-09-25 | 2023-09-25 | 一种多靶点祛眼袋组合物及其制备方法和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202311241403.0A CN117064769A (zh) | 2023-09-25 | 2023-09-25 | 一种多靶点祛眼袋组合物及其制备方法和应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN117064769A true CN117064769A (zh) | 2023-11-17 |
Family
ID=88711770
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202311241403.0A Pending CN117064769A (zh) | 2023-09-25 | 2023-09-25 | 一种多靶点祛眼袋组合物及其制备方法和应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN117064769A (zh) |
-
2023
- 2023-09-25 CN CN202311241403.0A patent/CN117064769A/zh active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN111249209B (zh) | 一种保湿修护霜及其制备方法 | |
CN111643404B (zh) | 一种屏障修护保湿面霜及其制备方法 | |
US6468564B1 (en) | Topical compositions containing lotus for skin treatment | |
DE60023816T2 (de) | Verwendung von Lycopin in Zusammensetzungen zur Behandlung von Hautalterungserscheinungen | |
CN111166683A (zh) | 一种富勒烯抗衰抗氧化美容护肤化妆品及其制备方法 | |
CN113197836A (zh) | 一种保湿舒缓止痒护肤乳霜及其制备方法 | |
CN113786376B (zh) | 一种具有去眼纹功效的眼霜组合物及其制备方法 | |
CN111588671A (zh) | 一种具有控油收敛功效的组合物、化妆品及其应用 | |
CN110302091B (zh) | 一种含烟酰胺腺嘌呤二核苷酸的抗皮肤衰老组合物及其制备方法和用途 | |
CN113693962A (zh) | 一种含纤连蛋白的多重蛋白修复组合物及其制备方法 | |
CN111773122A (zh) | 一种具有滋润功效的发热面膜及其制备方法 | |
CN112245315A (zh) | 一种具有保湿修复功效的神经酰胺面膜及其制备方法 | |
CN111658555A (zh) | 一种纳米抗皱精华乳及其制备方法 | |
CN111973501A (zh) | 一种神经酰胺赋活乳及其制备方法 | |
CN113332193A (zh) | 一种预防妊娠纹的组合物和按摩霜 | |
CN108392455A (zh) | 含有铁皮石斛提取物的护肤霜及其制备方法 | |
CN110721101A (zh) | 一种可自行调配的双组份精华霜及其制备方法 | |
CN103385838A (zh) | 祛斑美白乳液 | |
CN107496286B (zh) | 一种淡化细纹补水滋润型水乳及其制备方法 | |
CN117064769A (zh) | 一种多靶点祛眼袋组合物及其制备方法和应用 | |
KR101154772B1 (ko) | 대추 추출물 및 호두 추출물을 함유하는 피부 보습용화장료 조성물 | |
JP7305161B2 (ja) | 皮膚化粧料 | |
CN112402309A (zh) | 一种多维矿物精华霜及其制备方法 | |
KR102688309B1 (ko) | 피부장벽 형성인자를 유효성분으로 포함하는 보습 및 진정용 화장료 조성물 | |
CN112972276A (zh) | 一种保湿补水面霜及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |